FDA label
What is Jaypirca used for?
Jaypirca contains pirtobrutinib. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Jaypirca lists 3 uses: Mantle Cell Lymphoma; Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Jaypirca?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Jaypirca, tablet, coated
Indications and Usage, quoted from the label by Eli Lilly and Company (NDA216059). Cross-references to other label sections are left out.
Mantle Cell Lymphoma
JAYPIRCA® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion
JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
Source: DailyMed label, set id bd551845-0878-49a4-860f-839b83f6b801, version 16, effective October 2, 2026. NDC 0002-6902, one of 2 listings for this product.
Questions
What is Jaypirca used for?
The FDA label for Jaypirca lists 3 uses: Mantle Cell Lymphoma; Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion.
What drug class is Jaypirca?
FDA lists pirtobrutinib in the Kinase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.